ArticleSeminars in arthritis and rheumatism2025
Outcomes of respiratory syncytial virus infection in patients with systemic autoimmune rheumatic disease.
Article in Seminars in arthritis and rheumatism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vaccination in systemic lupus erythematosus.Human vaccines & immunotherapeutics · 2026Review
- Vaccination considerations in autoimmune rheumatic diseases.Nature reviews. Rheumatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) is a common respiratory viral illness which can cause severe outcomes in older and immunosuppressed populations. There is little data regarding RSV outcomes among people with systemic autoimmune rheumatic diseases (SARDs).
methodsThis retrospective cohort study examined risk factors for hospitalization in individuals with SARDs and documented RSV infection between 2015 and 2023 at Mass General Brigham (Boston, MA). Clinical data were collected from electronic health records. Multivariable adjusted logistic regression was used to identify factors associated with hospitalization for RSV infection.
resultsOf 188 individuals with SARDs and RSV (mean age 68.5 years, 75.5% female), 96 (51.0%) were hospitalized. Higher Charlson Comorbidity Index (aOR 1.16 per point, 95% CI: 1.04-1.31), Claims-Based Frailty Index (aOR 4.80 vs. robust/pre-frail, 95% CI: 2.32-9.94), and concurrent infection (aOR 2.52 vs. RSV alone, 95% CI: 1.07-5.92) were associated with increased odds of hospitalization. CD20 inhibitor treatment (aOR 3.84 vs. csDMARD, 95% CI: 0.99-15.20) and older age (OR 1.03 per year, 95% CI: 1.01-1.05) were associated with numerically increased odds of RSV hospitalization. Among hospitalized individuals, 56% required oxygen. There were 12 deaths within 90 days (12.5% of those hospitalized; 6% of all with RSV).
conclusionsThis study highlights the increased risk of severe outcomes of RSV infection in individuals with SARDs. Factors associated with RSV hospitalization included frailty, higher comorbidity burden, and concurrent infection at the time of RSV. These findings should inform clinical decisions regarding RSV vaccination and prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.